LDL cholesterol remains a primary clinical marker, while oxidized LDL is generally considered a specialty biomarker that may add context in selected cases
The evolutionary origin in lizard venom is now simply a fascinating footnote
So as with most with well with many pharmaceuticals certainly, there is a secondary effect of certain types of medication and in this case there was identified, you know, considerable weight loss in diabetics using GLP-1 receptor agonists
Expanding private healthcare services and better access to advanced treatment options areincreasing the use of GLP-1 therapies
We know about these interactions because Novo Nordisk, the manufacturer of FDA-approved Wegovy, Ozempic, and Rybelsus, is required to report adverse events to the FDA
Plans that cover GLP-1s for diabetes or cardiovascular conditions will cover pills and injectables alike